CJC-1295: A Modified GHRH Analog in Research

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) engineered for an extended plasma half-life. The compound was developed by ConjuChem Inc. in Canada and has been studied in published clinical trials — making it one of the better-characterized research peptides in terms of human pharmacokinetic data.

Background: Why Half-Life Matters for GHRH Analogs

Native GHRH is a 44-amino-acid peptide with a plasma half-life of only 6–8 minutes due to rapid cleavage by dipeptidyl peptidase-4 (DPP-4) at the N-terminus and other peptidases. This pharmacokinetic property means native GHRH would require very frequent dosing to sustain pituitary stimulation in a research or therapeutic context.

CJC-1295 was designed to address this limitation through two key strategies:

Amino acid substitutions at positions vulnerable to DPP-4 cleavage, particularly substituting Ala at position 2 with a D-Ala analog resistant to enzymatic attack
Drug Affinity Complex (DAC) technology — a maleimidoproprionic acid (MPA) linker that allows the compound to form a covalent bond with endogenous serum albumin after injection

The albumin binding is the primary determinant of CJC-1295's extended duration. Albumin has a plasma half-life of approximately 19 days; compounds bound to it effectively inherit a fraction of this long circulation time.

It is important to note that "CJC-1295" in research contexts sometimes refers to the DAC-containing version and sometimes to a non-DAC version (often called "CJC-1295 without DAC" or "Modified GRF(1-29)"). These are pharmacologically different compounds with significantly different half-lives. Published clinical trial data refers to the DAC-containing version.

Published Clinical Data

ConjuChem conducted Phase I/II clinical trials on CJC-1295 (with DAC) that were published in the peer-reviewed literature, including a paper in the Journal of Clinical Endocrinology and Metabolism (Teichman et al., 2006). This represents a level of published human evidence that distinguishes CJC-1295 from many research peptides.

Key findings from this trial included:

Dose-dependent increases in plasma GH AUC following single subcutaneous injections
Sustained elevation of plasma IGF-1 for up to 10–14 days after a single dose
A dose-dependent increase in mean 24-hour GH levels
The albumin-binding strategy appeared to function as designed — GH responses were prolonged well beyond what native GHRH produces

These are pharmacokinetic and pharmacodynamic observations, not clinical efficacy outcomes. The trial was not designed to measure body composition, performance, or health outcomes.

The DAC Mechanism and Its Implications

The DAC technology creates a reservoir of CJC-1295 in the circulation, continuously releasing active compound as albumin turns over. This sustained delivery changes the GH release profile from pulsatile (as seen with short-acting GHSs) to more continuous.

Whether continuous vs. pulsatile GH stimulation produces different biological outcomes is an active area of research. Some researchers have proposed that the pulsatile nature of physiological GH secretion is important for tissue responses, and that continuous stimulation may produce different downstream effects than pulse amplification. This question has not been definitively answered in the literature.

Combination Research with GHSs

CJC-1295 is frequently used in research in combination with GHS-class peptides (such as ipamorelin). The rationale is that GHRH analogs and GHS peptides work through different receptors and by potentially complementary mechanisms — GHRH (via GHRH-R) and GHS (via GHS-R1a) — so their combination may produce synergistic GH release.

Animal studies have examined this synergy, and the physiological principle of GHRH/ghrelin co-stimulation is well-established. However, the characterization of specific CJC-1295 + ipamorelin combinations in controlled human studies is limited.

What the Research Does Not Address

The clinical trial data on CJC-1295 provides pharmacokinetic information and short-term GH/IGF-1 effects. Researchers should be aware of what is not established:

Long-term safety data beyond the study periods reported
Effects on body composition in non-deficient populations
Comparison to standard-of-care GH replacement in GH-deficient subjects
Efficacy for any specific clinical indication (ConjuChem's development program was discontinued before phase III)

CJC-1295 with DAC has been studied to a greater extent than most peptides in this class, but the available human evidence still falls significantly short of what would be required for regulatory approval of any therapeutic claim.